Vaxart

Vaxart is a biotechnology company that specializes in the development of oral recombinant vaccines. The company's proprietary technology platform is a novel approach to vaccine development, designed to allow for the oral administration of vaccines through a tablet, rather than by injection.

History[edit | edit source]

Vaxart was founded in 2004 with the goal of developing a new method of vaccine delivery that would improve the effectiveness and convenience of immunization. The company's initial focus was on the development of vaccines for influenza and norovirus, but it has since expanded its research and development efforts to include a range of other infectious diseases.

Technology[edit | edit source]

Vaxart's technology platform is based on the use of recombinant adenovirus vectors to deliver vaccine antigens to the immune system. This approach allows for the oral administration of vaccines, which has several potential advantages over traditional injection-based methods. These include improved patient compliance, the ability to stimulate a broader immune response, and the potential for mass distribution in the event of a pandemic.

Products[edit | edit source]

Vaxart's product pipeline includes vaccines for a number of infectious diseases, including influenza, norovirus, respiratory syncytial virus (RSV), and coronavirus disease 2019 (COVID-19). The company's influenza vaccine has completed Phase 2 clinical trials, while its norovirus and RSV vaccines are in preclinical development. In 2020, Vaxart initiated a Phase 1 clinical trial for its oral COVID-19 vaccine.

Financials[edit | edit source]

As a publicly traded company, Vaxart's financial performance is closely watched by investors. The company's revenue is primarily derived from collaboration agreements, licensing fees, and government grants. In recent years, Vaxart has received significant funding from the Biomedical Advanced Research and Development Authority (BARDA) to support the development of its influenza and norovirus vaccines.